Cargando…

A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-κB Signal Pathway and Reducing Reactive Oxygen Species

Dysregulation of osteoclast-osteoblast balance, resulting in abnormal bone remodeling, is responsible for postmenopausal osteoporosis (PMOP) or other secondary forms of osteoporosis. We demonstrated that dictamnine (DIC), a novel RANKL-targeted furoquinoline alkaloid, inhibits osteoclastogenesis by...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Puiian, Lv, Zheng, Li, Jinglan, Wei, Qiushi, Xu, LiangLiang, Fang, Bin, Luo, Yiwen, He, Mincong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652067/
https://www.ncbi.nlm.nih.gov/pubmed/36388169
http://dx.doi.org/10.1155/2022/5982014
_version_ 1784828384804601856
author Wong, Puiian
Lv, Zheng
Li, Jinglan
Wei, Qiushi
Xu, LiangLiang
Fang, Bin
Luo, Yiwen
He, Mincong
author_facet Wong, Puiian
Lv, Zheng
Li, Jinglan
Wei, Qiushi
Xu, LiangLiang
Fang, Bin
Luo, Yiwen
He, Mincong
author_sort Wong, Puiian
collection PubMed
description Dysregulation of osteoclast-osteoblast balance, resulting in abnormal bone remodeling, is responsible for postmenopausal osteoporosis (PMOP) or other secondary forms of osteoporosis. We demonstrated that dictamnine (DIC), a novel RANKL-targeted furoquinoline alkaloid, inhibits osteoclastogenesis by facilitating the activities of reactive oxygen species (ROS), NF-κB, and NFATc1 in vitro and prevents the development of OVX-induced osteoporosis mouse models in vivo. Methods. The docking mechanism of DIC and RANKL was initially identified by protein–ligand molecular docking. RNA sequencing was performed and analyzed to reveal the potential mechanism and signaling pathway of the antiosteoporosis effects of DIC. To verify the sequencing results, we examined the impact of DIC on RANKL-induced osteoclast differentiation, bone resorption, F-actin ring production, ROS generation, and NF-κB activation in osteoclasts in vitro. Moreover, a luciferase assay was performed to determine the binding and transcriptional activity of Nrf2 and NF-κB. The in vivo efficacy of DIC was assessed with an ovariectomy- (OVX-) induced osteoporosis model, which was analyzed using micro-CT and bone histomorphometry. Results. The molecular docking results indicated that DIC could bind particularly to RANKL. RNA-seq confirmed that DIC could regulate the osteoclast-related pathway. DIC suppressed osteoclastogenesis, bone resorption, F-actin belt formation, osteoclast-specific gene expression, and ROS activity by preventing NFATc1 expression and affecting NF-κB signaling pathways in vitro. The luciferase assay showed that DIC not only suppressed the activity of Nrf2 but also contributed to the combination of Nrf2 and NF-κB. Our in vivo study indicated that DIC protects against OVX-induced osteoporosis and preserves bone volume by inhibiting osteoclast activity and function. Conclusions. DIC can ameliorate osteoclast formation and OVX-induced osteoporosis and therefore is a potential therapeutic treatment for osteoporosis.
format Online
Article
Text
id pubmed-9652067
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-96520672022-11-15 A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-κB Signal Pathway and Reducing Reactive Oxygen Species Wong, Puiian Lv, Zheng Li, Jinglan Wei, Qiushi Xu, LiangLiang Fang, Bin Luo, Yiwen He, Mincong Oxid Med Cell Longev Research Article Dysregulation of osteoclast-osteoblast balance, resulting in abnormal bone remodeling, is responsible for postmenopausal osteoporosis (PMOP) or other secondary forms of osteoporosis. We demonstrated that dictamnine (DIC), a novel RANKL-targeted furoquinoline alkaloid, inhibits osteoclastogenesis by facilitating the activities of reactive oxygen species (ROS), NF-κB, and NFATc1 in vitro and prevents the development of OVX-induced osteoporosis mouse models in vivo. Methods. The docking mechanism of DIC and RANKL was initially identified by protein–ligand molecular docking. RNA sequencing was performed and analyzed to reveal the potential mechanism and signaling pathway of the antiosteoporosis effects of DIC. To verify the sequencing results, we examined the impact of DIC on RANKL-induced osteoclast differentiation, bone resorption, F-actin ring production, ROS generation, and NF-κB activation in osteoclasts in vitro. Moreover, a luciferase assay was performed to determine the binding and transcriptional activity of Nrf2 and NF-κB. The in vivo efficacy of DIC was assessed with an ovariectomy- (OVX-) induced osteoporosis model, which was analyzed using micro-CT and bone histomorphometry. Results. The molecular docking results indicated that DIC could bind particularly to RANKL. RNA-seq confirmed that DIC could regulate the osteoclast-related pathway. DIC suppressed osteoclastogenesis, bone resorption, F-actin belt formation, osteoclast-specific gene expression, and ROS activity by preventing NFATc1 expression and affecting NF-κB signaling pathways in vitro. The luciferase assay showed that DIC not only suppressed the activity of Nrf2 but also contributed to the combination of Nrf2 and NF-κB. Our in vivo study indicated that DIC protects against OVX-induced osteoporosis and preserves bone volume by inhibiting osteoclast activity and function. Conclusions. DIC can ameliorate osteoclast formation and OVX-induced osteoporosis and therefore is a potential therapeutic treatment for osteoporosis. Hindawi 2022-11-04 /pmc/articles/PMC9652067/ /pubmed/36388169 http://dx.doi.org/10.1155/2022/5982014 Text en Copyright © 2022 Puiian Wong et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wong, Puiian
Lv, Zheng
Li, Jinglan
Wei, Qiushi
Xu, LiangLiang
Fang, Bin
Luo, Yiwen
He, Mincong
A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-κB Signal Pathway and Reducing Reactive Oxygen Species
title A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-κB Signal Pathway and Reducing Reactive Oxygen Species
title_full A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-κB Signal Pathway and Reducing Reactive Oxygen Species
title_fullStr A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-κB Signal Pathway and Reducing Reactive Oxygen Species
title_full_unstemmed A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-κB Signal Pathway and Reducing Reactive Oxygen Species
title_short A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-κB Signal Pathway and Reducing Reactive Oxygen Species
title_sort novel rankl-targeted furoquinoline alkaloid ameliorates bone loss in ovariectomized osteoporosis through inhibiting the nf-κb signal pathway and reducing reactive oxygen species
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652067/
https://www.ncbi.nlm.nih.gov/pubmed/36388169
http://dx.doi.org/10.1155/2022/5982014
work_keys_str_mv AT wongpuiian anovelrankltargetedfuroquinolinealkaloidamelioratesbonelossinovariectomizedosteoporosisthroughinhibitingthenfkbsignalpathwayandreducingreactiveoxygenspecies
AT lvzheng anovelrankltargetedfuroquinolinealkaloidamelioratesbonelossinovariectomizedosteoporosisthroughinhibitingthenfkbsignalpathwayandreducingreactiveoxygenspecies
AT lijinglan anovelrankltargetedfuroquinolinealkaloidamelioratesbonelossinovariectomizedosteoporosisthroughinhibitingthenfkbsignalpathwayandreducingreactiveoxygenspecies
AT weiqiushi anovelrankltargetedfuroquinolinealkaloidamelioratesbonelossinovariectomizedosteoporosisthroughinhibitingthenfkbsignalpathwayandreducingreactiveoxygenspecies
AT xuliangliang anovelrankltargetedfuroquinolinealkaloidamelioratesbonelossinovariectomizedosteoporosisthroughinhibitingthenfkbsignalpathwayandreducingreactiveoxygenspecies
AT fangbin anovelrankltargetedfuroquinolinealkaloidamelioratesbonelossinovariectomizedosteoporosisthroughinhibitingthenfkbsignalpathwayandreducingreactiveoxygenspecies
AT luoyiwen anovelrankltargetedfuroquinolinealkaloidamelioratesbonelossinovariectomizedosteoporosisthroughinhibitingthenfkbsignalpathwayandreducingreactiveoxygenspecies
AT hemincong anovelrankltargetedfuroquinolinealkaloidamelioratesbonelossinovariectomizedosteoporosisthroughinhibitingthenfkbsignalpathwayandreducingreactiveoxygenspecies
AT wongpuiian novelrankltargetedfuroquinolinealkaloidamelioratesbonelossinovariectomizedosteoporosisthroughinhibitingthenfkbsignalpathwayandreducingreactiveoxygenspecies
AT lvzheng novelrankltargetedfuroquinolinealkaloidamelioratesbonelossinovariectomizedosteoporosisthroughinhibitingthenfkbsignalpathwayandreducingreactiveoxygenspecies
AT lijinglan novelrankltargetedfuroquinolinealkaloidamelioratesbonelossinovariectomizedosteoporosisthroughinhibitingthenfkbsignalpathwayandreducingreactiveoxygenspecies
AT weiqiushi novelrankltargetedfuroquinolinealkaloidamelioratesbonelossinovariectomizedosteoporosisthroughinhibitingthenfkbsignalpathwayandreducingreactiveoxygenspecies
AT xuliangliang novelrankltargetedfuroquinolinealkaloidamelioratesbonelossinovariectomizedosteoporosisthroughinhibitingthenfkbsignalpathwayandreducingreactiveoxygenspecies
AT fangbin novelrankltargetedfuroquinolinealkaloidamelioratesbonelossinovariectomizedosteoporosisthroughinhibitingthenfkbsignalpathwayandreducingreactiveoxygenspecies
AT luoyiwen novelrankltargetedfuroquinolinealkaloidamelioratesbonelossinovariectomizedosteoporosisthroughinhibitingthenfkbsignalpathwayandreducingreactiveoxygenspecies
AT hemincong novelrankltargetedfuroquinolinealkaloidamelioratesbonelossinovariectomizedosteoporosisthroughinhibitingthenfkbsignalpathwayandreducingreactiveoxygenspecies